Literature DB >> 34051771

The burden of hip and knee osteoarthritis in Finnish occupational healthcare.

Milla Summanen1, Liisa Ukkola-Vuoti2, Samu Kurki3, Samuli Tuominen2, Rami Madanat4.   

Abstract

BACKGROUND: Osteoarthritis (OA) is a leading cause of disability and pain especially among older adults, but it is also known to affect working age individuals, often leading to reduced productivity and increased healthcare usage. The aim of this study was to determine the burden of hip and knee OA in Finnish occupational healthcare.
METHODS: This was a retrospective registry study utilizing the electronic medical records of the largest private and occupational healthcare provider in Finland. All consented patients with hip or knee OA were identified. A subcohort of occupational healthcare (OCH) patients was then compared to an age- and gender-matched control group without OA. Patient demographics including comorbidities were determined and healthcare contacts, medication prescriptions, and sick leaves were compared between the two groups. The study period was from January 1st, 2012 to April 30th, 2020.
RESULTS: 51,068 patients with hip or knee OA were identified (all OA cohort) and 35,109 of these formed the occupational healthcare subcohort. Most of the OA patients were female and belonged to the age group 50-59 years. The point prevalence of hip/knee OA at the end of the study period was 5.6% for the occupational healthcare subcohort. OA patients had 2.2 times more healthcare contacts and 2.8 times more overall sick leave days compared to the age- and gender-matched control cohort. Etoricoxib was the most commonly prescribed medication at OA-related visits (21.8% of patients). Opioids were prescribed to 10.6% of patients at OA-related visits and the most prescribed opioid was a combination of codeine and paracetamol (4.8% of patients). 5054 OA patients (14.4%) had a contraindication for non-steroidal anti-inflammatory drugs (NSAIDs).
CONCLUSIONS: This retrospective registry study utilizing real-world data provides new evidence on the disease burden of hip or knee osteoarthritis from the electronic medical records of Finnish occupational healthcare customers. OA patients had more comorbidities, more healthcare contacts, more sick leave days, and more analgesic prescriptions compared to an age- and gender-matched control cohort without OA.

Entities:  

Keywords:  Burden of disease; Healthcare resource utilization; Occupational healthcare; Osteoarthritis; Real world data; Registry study

Year:  2021        PMID: 34051771     DOI: 10.1186/s12891-021-04372-9

Source DB:  PubMed          Journal:  BMC Musculoskelet Disord        ISSN: 1471-2474            Impact factor:   2.362


  12 in total

Review 1.  Taking the patient and the patient's perspective into account to improve outcomes of care of patients with musculoskeletal diseases.

Authors:  Martijn A H Oude Voshaar; Mart A F J van de Laar
Journal:  Best Pract Res Clin Rheumatol       Date:  2019-09-06       Impact factor: 4.098

2.  Risk of work loss due to illness or disability in patients with osteoarthritis: a population-based cohort study.

Authors:  Behnam Sharif; Rochelle Garner; Claudia Sanmartin; William M Flanagan; Deirdre Hennessy; Deborah A Marshall
Journal:  Rheumatology (Oxford)       Date:  2016-01-11       Impact factor: 7.580

3.  Analgesic use in patients with knee and/or hip osteoarthritis referred to an outpatient center: a cross-sectional study within the Amsterdam Osteoarthritis Cohort.

Authors:  Jesper Knoop; Joyce van Tunen; Martin van der Esch; Leo D Roorda; Joost Dekker; Marike van der Leeden; Willem F Lems
Journal:  Rheumatol Int       Date:  2017-08-18       Impact factor: 2.631

Review 4.  The epidemiology of osteoarthritis.

Authors:  Victoria L Johnson; David J Hunter
Journal:  Best Pract Res Clin Rheumatol       Date:  2014-02       Impact factor: 4.098

5.  Osteoarthritis and absenteeism costs: evidence from US National Survey Data.

Authors:  Harry Kotlarz; Candace L Gunnarsson; Hai Fang; John A Rizzo
Journal:  J Occup Environ Med       Date:  2010-03       Impact factor: 2.162

Review 6.  The individual and socioeconomic impact of osteoarthritis.

Authors:  David J Hunter; Deborah Schofield; Emily Callander
Journal:  Nat Rev Rheumatol       Date:  2014-03-25       Impact factor: 20.543

7.  Impact of self-rated osteoarthritis severity in an employed population: cross-sectional analysis of data from the national health and wellness survey.

Authors:  Marco Dacosta Dibonaventura; Shaloo Gupta; Margaret McDonald; Alesia Sadosky; Dan Pettitt; Stuart Silverman
Journal:  Health Qual Life Outcomes       Date:  2012-03-15       Impact factor: 3.186

8.  Frequency and predictors of premature work loss in primary care consulters for osteoarthritis: prospective cohort study.

Authors:  Ross Wilkie; Chris Phillipson; Elaine Hay; Glenn Pransky
Journal:  Rheumatology (Oxford)       Date:  2013-10-17       Impact factor: 7.580

9.  Epidemiology of knee osteoarthritis in general practice: a registry-based study.

Authors:  David Spitaels; Pavlos Mamouris; Bert Vaes; Miek Smeets; Frank Luyten; Rosella Hermens; Patrik Vankrunkelsven
Journal:  BMJ Open       Date:  2020-01-20       Impact factor: 2.692

10.  Existing comorbidities in people with osteoarthritis: a retrospective analysis of a population-based cohort in Alberta, Canada.

Authors:  Deborah A Marshall; Xiaoxiao Liu; Cheryl Barnabe; Karen Yee; Peter D Faris; Claire Barber; Dianne Mosher; Thomas Noseworthy; Jason Werle; Lisa Lix
Journal:  BMJ Open       Date:  2019-11-21       Impact factor: 2.692

View more
  2 in total

1.  Clinical therapeutic effects of combined diacerein and glucosamine in the treatment of osteoarthritis: A protocol for systematic review and meta-analysis.

Authors:  Fei Wang; Wei-Xing Shi; Jie Chen; Kang He; Wei Fang
Journal:  Medicine (Baltimore)       Date:  2021-11-24       Impact factor: 1.817

Review 2.  Integrins, cadherins and channels in cartilage mechanotransduction: perspectives for future regeneration strategies.

Authors:  Martin Philipp Dieterle; Ayman Husari; Bernd Rolauffs; Thorsten Steinberg; Pascal Tomakidi
Journal:  Expert Rev Mol Med       Date:  2021-10-27       Impact factor: 5.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.